A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease.
Ida Unhammer NjerveSissel ÅkraThomas W WeissSvein SolheimReidun ØvstebøHans Christian D AassRune ByrkjelandHarald ArnesenIngebjørg SeljeflotPublished in: Mediators of inflammation (2017)
In our small cohort of patients with combined T2DM and CAD, a possible anti-inflammatory effect of saxagliptin, observed in the present study by upregulation of IL-10 in leukocytes, needs to be confirmed in larger studies.
Keyphrases
- anti inflammatory
- coronary artery disease
- type diabetes
- glycemic control
- poor prognosis
- percutaneous coronary intervention
- cell proliferation
- coronary artery bypass grafting
- randomized controlled trial
- signaling pathway
- insulin resistance
- heart failure
- stem cells
- skeletal muscle
- adipose tissue
- double blind
- left ventricular
- mesenchymal stem cells
- weight loss